8-K: Cocrystal Pharma Q3 2025: Norovirus Study & Funding Boost

Cocrystal Pharma reported reduced Q3 2025 net losses and R&D expenses, secured new funding, and advanced its norovirus and influenza antiviral programs.

Summary

• Net loss for the third quarter of 2025 was $2.0 million, or $0.19 per share, a significant reduction from $4.9 million, or $0.49 per share, in Q3 2024.
• Net loss for the first nine months of 2025 was $6.4 million, or $0.61 per share, compared to $14.2 million, or $1.40 per share, for the same period in 2024.
• Research and development (R&D) expenses decreased to $954,000 in Q3 2025 from $3.2 million in Q3 2024, primarily due to the timing of clinical study costs.
• General and administrative (G&A) expenses decreased to $1.1 million in Q3 2025 from $1.8 million in Q3 2024, mainly due to a reduction in compensation expense.
• Unrestricted cash as of September 30, 2025, was $7.7 million, which included $4.7 million in gross proceeds from a registered direct financing completed in September 2025.
• The company received FDA IND clearance to evaluate CDI-988 as both a norovirus preventive and treatment, with a Phase 1b norovirus challenge study expected to initiate enrollment in Q1 2026.
• A $500,000 Small Business Innovation Research (SBIR) award was granted by the National Institutes of Health (NIH) to advance the influenza A/B replication inhibitor program.
• The CC-42344 Phase 2a human challenge study for influenza A was completed in November 2025, showing a favorable safety and tolerability profile, but efficacy analyses were not reported due to issues in trial conduct.

Sentiment

Score: 7

Explanation: The company reported significantly improved financial metrics with reduced net losses and operating expenses, and achieved a key regulatory milestone with FDA IND clearance for its norovirus program. New funding also strengthens the balance sheet. However, the lack of efficacy data for the CC-42344 influenza study due to trial conduct issues introduces a notable negative, balancing the overall positive sentiment.

Positives

• Net loss significantly decreased to $2.0 million in Q3 2025 from $4.9 million in Q3 2024, and to $6.4 million for the first nine months of 2025 from $14.2 million in the prior year period.
• R&D expenses were substantially reduced to $954,000 in Q3 2025 from $3.2 million in Q3 2024, reflecting efficient management of clinical study costs.
• G&A expenses decreased to $1.1 million in Q3 2025 from $1.8 million in Q3 2024, primarily due to reduced compensation expense.
• Received FDA IND clearance for the CDI-988 Phase 1b norovirus challenge study, a key regulatory milestone, with enrollment anticipated in Q1 2026.
• Secured a $500,000 NIH SBIR award for the influenza A/B program, validating the company's structure-based drug discovery platform technology.
• Strengthened the balance sheet through recent financings, including $4.7 million in gross proceeds from a registered direct offering in September 2025 and $1.03 million from a private placement in October 2025.
• CDI-988 demonstrated superior broad-spectrum antiviral activity against GII.17 norovirus strains, which were the most prevalent in the U.S. and Europe in 2024-2025.
• The CC-42344 Phase 2a influenza A study completed with a favorable safety and tolerability profile, reporting no serious adverse events (SAEs) or drug-related discontinuations.

Negatives

• Efficacy analyses for the CC-42344 Phase 2a human challenge study were not reported due to issues in trial conduct, which is a significant setback for the program.
• The CC-42344 Phase 2a study had previously been extended in December 2024 due to unexpectedly low influenza infection among study participants, indicating challenges in trial execution.
• Unrestricted cash decreased from $9.9 million as of December 31, 2024, to $7.7 million as of September 30, 2025, despite recent capital raises.
• Net cash used in operating activities for the first nine months of 2025 was $6.5 million, indicating continued cash burn.

Risks

• The need for additional capital to fund operations and the ability to obtain such capital on favorable terms or at all.
• Risks and uncertainties arising from inflation, the possibility of a recession, interest rate increases, imposed and threatened tariffs, and geopolitical conflicts (including those in Ukraine and Israel) on the company, its collaboration partners, and global economies.
• Manufacturing and research delays arising from raw materials and labor shortages, supply chain disruptions, and other business interruptions.
• Adverse impacts on the ability to obtain raw materials for and otherwise proceed with studies, as well as similar problems with vendors, clinical research organizations (CROs), and contract manufacturing organizations (CMOs).
• The progress and results of studies, including any adverse findings or delays.
• The ability to recruit volunteers for, and to otherwise proceed with, clinical studies.
• The company's and its collaboration partners' technology and software not performing as expected.
• Financial difficulties experienced by certain partners.
• General risks arising from clinical studies.
• Receipt of regulatory approvals, regulatory changes, and any adverse developments which may arise therefrom.
• Potential mutations in a virus being targeted that may result in variants resistant to a product candidate.
• The potential for the development of effective treatments by competitors which could reduce or eliminate a prospective future market share.
• The ability to meet future liquidity needs.

Future Outlook

The company expects to begin enrolling participants in the first quarter of 2026 for its norovirus challenge study evaluating CDI-988. It plans to continue the development of oral CC-42344 as a treatment for pandemic and seasonal influenza A. The company also anticipates potential future capital from the exercise of warrants issued in recent financings.

Management Comments

• Sam Lee, Ph.D., President and co-CEO: "We expect to begin enrolling participants in the first quarter of 2026 for our norovirus challenge study evaluating CDI-988, our oral broad-spectrum protease inhibitor. This study will provide an initial assessment of CDI-988 for both prevention and treatment of norovirus infection."
• Sam Lee, Ph.D., President and co-CEO: "We were honored to receive a Small Business Innovation (SBIR) award from the National Institutes of Health (NIH) to advance our work in developing a novel, broad-spectrum lead candidate targeting the influenza A/B polymerase complex. This recognition further validates the strength of our structure-based drug discovery platform technology and its capability to develop innovative antiviral therapies for addressing unmet medical needs."
• James Martin, CFO and co-CEO: "Together with the non-dilutive SBIR award, we strengthened our balance sheet through two recent at-the-market financings under Nasdaq rules. This enhanced cash position supports the continued development of our product pipeline, including our potentially groundbreaking norovirus program."

Industry Context

Cocrystal Pharma operates in the critical antiviral drug development sector, addressing significant global health threats such as norovirus and influenza, which currently lack effective treatments or are burdened by viral resistance. Norovirus alone accounts for 685 million global cases annually and a $60 billion worldwide economic impact, while influenza causes approximately 1 billion cases and up to 650,000 deaths worldwide each year. The company's structure-based drug discovery platform aims to develop next-generation, broad-spectrum antivirals that target highly conserved viral regions, offering a potential advantage against viral mutations and minimizing off-target side effects. This approach is particularly relevant given the emergence of highly pathogenic avian influenza viruses and the estimated $16 billion annual global COVID-19 therapeutics market by 2031, highlighting the substantial unmet medical needs and market opportunities for effective antiviral therapies.

Related Party Transactions

• Operating lease right-of-use assets, net, include $115,000 (as of September 30, 2025) and $152,000 (as of December 31, 2024) related to a related party.
• Current maturities of operating lease liabilities include $54,000 (as of September 30, 2025) and $49,000 (as of December 31, 2024) related to a related party.
• Long-term operating lease liabilities include $63,000 (as of September 30, 2025) and $104,000 (as of December 31, 2024) related to a related party.

Stakeholder Impact

• Shareholders: The significant reduction in net losses and operating expenses, along with new capital raises, could be viewed positively. However, the dilution from new share issuance and potential future warrant exercises, coupled with the lack of efficacy data for the CC-42344 influenza program, introduces uncertainty regarding future stock performance. Pipeline progress offers long-term value potential.
• Employees: Continued advancement of drug development programs and securing new funding suggest ongoing stability and opportunities within the company.
• Customers (future patients): Progress in the norovirus and influenza programs offers hope for novel treatments for highly contagious and impactful diseases, addressing significant unmet medical needs.
• Creditors: Improved financial metrics, including reduced net losses and lower cash burn, along with a strengthened cash position from recent financings, could enhance the company's creditworthiness.
• Regulatory Authorities (FDA, NIH): Successful IND clearance and receipt of an NIH award demonstrate the company's adherence to regulatory standards and scientific merit, fostering continued collaboration and trust.

Next Steps

• Initiate enrollment for the CDI-988 Phase 1b norovirus challenge study in the first quarter of 2026.
• Continue development of oral CC-42344 as a treatment for pandemic and seasonal influenza A.
• Advance the novel, broad-spectrum lead candidate targeting the influenza A/B polymerase complex with the NIH SBIR award.
• Potentially receive additional capital from the exercise of outstanding warrants.

Key Dates

Recommendation

While Cocrystal Pharma demonstrated significant financial improvements with reduced net losses and operating expenses, and achieved a crucial regulatory milestone with FDA IND clearance for its norovirus program, the lack of efficacy data for the CC-42344 influenza study due to trial conduct issues is a notable concern. The recent capital raises provide a cash runway but also involve dilution. The pipeline progress is promising, but the company remains in clinical stages with inherent risks associated with drug development and significant future capital needs. A 'Hold' recommendation reflects the balance between positive financial and pipeline advancements and the ongoing clinical and financial uncertainties.

Keywords

Antiviral, Norovirus, Influenza, CDI-988, CC-42344, Clinical Trials, Biotechnology, Drug Development, SEC Filing, Financial Results, Cocrystal Pharma, Nasdaq, COCP, SBIR, FDA, NIH, SARS-CoV-2, Coronavirus